Ligand Pharmaceuticals Incorporated (LGND) Q1 2012 Earnings Results

Ligand Pharmaceuticals Misses on EPS, Stock Up 2.15%

Ligand Pharmaceuticals reported a loss in EPS, which was significantly below expectations, indicating challenges in the current business environment. However, the stock rose by 2.15%, suggesting that investors may be optimistic about the company's long-term strategies and potential future growth. The lack of revenue details and guidance may leave some investors cautious, but the stock's positive reaction indicates some confidence in management's approach.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.03	N/A	-250.00%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Overall, management expressed concerns about the recent performance but remains committed to long-term growth strategies. They did not provide specific guidance for the upcoming quarters.

Management acknowledged the unexpected EPS loss and emphasized their focus on future projects.

They highlighted ongoing investments in research and development despite current challenges.

Ligand Pharmaceuticals Misses on EPS, Stock Up 2.15%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Misses on EPS, Stock Up 2.15%

Key numbers

Management commentary